Corvus Pharmaceuticals, Inc. CRVS
11.62
(0.18)
(1.53%)
as of 25 Sep
- Market cap
- $992.6M
- P/E
- 0.0×
Follow CRVS
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (18.98%) | (13.13%) | (32.60%) | (95.52%) |
+8 more TTM periods Free account |
|
| (17.64%) | (12.18%) | (21.83%) | (57.73%) | ||
ROIC |
(352.49%) | (755.45%) | (602.85%) | (399.52%) | |
Return on Tangible Assets |
(13.93%) | (8.35%) | (31.16%) | (68.04%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.49) | (0.39) | (0.42) | (0.39) | |
Free Cash Flow |
(45.23) | (35.14) | (32.97) | (32.21) | |
Capital Expenditures |
(0.70) | (0.23) | (0.17) | (0.14) | |
| Other line items | |||||
Cash ROIC |
(10.11%) | (7.31%) | (27.80%) | (23.33%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.54 | 1.83 | 2.15 | 0.80 | |
Depreciation/Fixed assets |
(0.52) | (3.40) | (5.64) | (5.55) | |
Capex/Depreciation |
1.60 | 0.24 | 0.14 | 0.12 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.48) | (0.39) | (0.42) | (0.39) | |
Capex per Share |
(0.01) | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates